PacBio is hard to break down to a sound bite, but that could spell opportunity for long-term investors.
A look at Berkshire Hathaway's recent moves.
What to look at when you're looking ahead.
There's one easy way to take a big bite out of your expenses.
This American is going to try.
Beta won't find it for you.
Growth investing in tough times can be tough, but don't give up.
Flat may be trendy, but there a lot of advantages to being vertical.
The drug company is banking on a generic for blood clots and heart problems.
In biotech investing, it pays to close your ears to all the hubbub.
Swing for the fences with this drug company.
The pharmaceutical's reorganization plan practically posts a "for sale" sign.
Once a small biotech struggling to make its way in the world, Amgen has grown up.
Health savings accounts can help you reduce costs -- if you know how they work.
Three keys to identifying promising biotech companies before the rest of the market.
One woman's journey should be a lesson to us all.
The relatively new health savings accounts make going it alone a whole lot easier than it was a few years ago.
Channel stuffing in the pharmaceutical industry and elsewhere can mask the condition of a company's financials and cost investors gold.
Drug companies are working on novel new ways to battle the bulge. Which pharmas' efforts might fatten your portfolio?